Evidence map›Paper›PMID 41057212›Full record

ArticleLupus science & medicine2025

Prediction model for renal outcomes in Latin American Mestizo patients with pure proliferative lupus nephritis.

Arturo Villalobos Navarro, Marc Xipell, Estefanía Garduño Hernández, Ricardo Valjalo, Francisco Contreras, Andrea Ruiz de Arechavaleta, Paula Segura, Daniel Miranda, Eduardo Ávila, María José Hidalgo and 10 more

Abstract readMulticenter Study
In one paragraph

Article in Lupus science & medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Arturo Villalobos Navarro *Department of Nephrology and Renal Transplantation, Hospital Barros Luco Trudeau, Santiago, Chile.
Marc Xipell *Department of Nephrology and Renal Transplantation, Hospital Clínic de Barcelona, Barcelona, Spain.
Estefanía Garduño HernándezDepartment of Nephrology, UMAE Hospital de Especialidades 'Dr. Bernardo Sepúlveda G' Centro Médico Nacional 21 Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
Ricardo ValjaloDepartment of Medicine, Hospital Del Salvador, Santiago, Chile.
Francisco ContrerasDepartment of Medicine, Hospital Clínico San Borja Arriarán, Santiago, Chile.
Andrea Ruiz de ArechavaletaDepartment of Medicine, Clinica Davila, Santiago, Chile.
Paula SeguraDepartment of Anatomic Pathology, Hospital Clinico de la Universidad de Chile Jose Joaquin Aguirre, Santiago, Chile.
Daniel MirandaDepartment of Nephrology, Hospital San Juan de Dios, Santiago, Chile.
Eduardo ÁvilaDepartment of Nephrology, Pontificia Universidad Católica de Chile, Santiago, Chile.
María José HidalgoDepartment of Nephrology, Hospital Clinico de la Universidad de Chile Jose Joaquin Aguirre, Santiago, Chile.
Juan Daniel Diaz GarciaDepartment of Nephrology and Renal Transplantation, General Hospital of Mexico, Mexico City, Mexico.ORCID 0000-0002-0739-0449
Fabiola Pazos PérezDepartment of Nephrology, UMAE Hospital de Especialidades 'Dr. Bernardo Sepúlveda G' Centro Médico Nacional 21 Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
Diana Valderrama ÁvilaDepartment of Nephrology, UMAE Hospital de Especialidades 'Dr. Bernardo Sepúlveda G' Centro Médico Nacional 21 Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
María Inés Gil ArredondoDepartment of Nephrology, UMAE Hospital de Especialidades 'Dr. Bernardo Sepúlveda G' Centro Médico Nacional 21 Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
Elena GuillénDepartment of Nephrology and Renal Transplantation, Hospital Clínic de Barcelona, Barcelona, Spain.
Ricard CerveraHospital Clinic de Barcelona Servei de Malalties Autoimmunes, Barcelona, Spain.
Gerard EspinosaHospital Clinic de Barcelona Servei de Malalties Autoimmunes, Barcelona, Spain.ORCID 0000-0003-1336-0163
Arturo PereiraDepartment of Hematology, Hospital Clinic de Barcelona, Barcelona, Spain.
Miquel BlascoDepartment of Nephrology and Renal Transplantation, Hospital Clínic de Barcelona, Barcelona, Spain.
Luis F QuintanaDepartment of Nephrology and Renal Transplantation, Hospital Clínic de Barcelona, Barcelona, Spain lfquinta@clinic.cat.ORCID 0000-0001-7582-8476

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveLupus nephritis (LN) is associated with a poorer prognosis in Latin American populations. However, the contributing risk factors contributing to this remain to be fully elucidated. This study aimed to develop a prognostic model for poor renal outcomes in patients of mestizo descent.

methodsWe conducted a multicentre, retrospective analysis including 290 adult mestizo patients with incident, biopsy-proven pure proliferative LN (International Society of Nephrology/Renal Pathology Society (ISN/RPS) class III or IV) from nine Chilean hospitals. Clinical, biological and histological variables were assessed. The primary outcome was a composite of stage IV/V chronic kidney disease, dialysis or death. Predictive variables were selected using multivariable Cox regression, and prognostic scores were derived accordingly. Internal validation was performed via bootstrapping. External validation included 93 Mexican patients, with model performance assessed using Harrel's concordance index.

resultsTwo baseline factors were independently associated with poor renal outcome: estimated glomerular filtration rate <30 mL/min/m

conclusionsBased on two readily available features at the time of diagnosis, the proposed model effectively stratifies Latin American mestizo patients with pure proliferative LN (ISN/RPS class III or IV) into three risk categories for poor renal outcome. This tool may support improved risk-based management in this high-risk population.

Indexed as

Lupus NephritisRenal Insufficiency, ChronicAdultChileFemaleGlomerular Filtration RateHumansKidneyMaleMexicoMiddle AgedPrognosisProportional Hazards ModelsRenal DialysisRetrospective StudiesRisk FactorsLupus Erythematosus, SystemicLupus NephritisRisk Factors

Identifiers

PMID41057212
PMCPMC12506453

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.